Alder BioPharmaceuticals (ALDR) Tops Q3 EPS by 83c

Alder BioPharmaceuticals (NASDAQ: ALDR) reported Q3 EPS of $0.88, $0.83 better than the analyst estimate of $0.05. Revenue for the quarter came in at $38.75 million versus the consensus estimate of $14.84 million.

For earnings history and earnings-related data on Alder BioPharmaceuticals (ALDR) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Aon names interim CFO as Edmund Reese exits the firm